3:12PM Barr Pharma says court denies preliminary injunction to halt generic Allegra sales (BRL) 63.89 0.29 : Co confirms that the US District Court for the District of New Jersey has denied a motion filed by Aventis Pharma (SNY) and Albany Molecular Research (AMRI) that would have forced BRL and Teva Pharma (TEVA) to cease marketing Fexofenadine Hydrochloride 30 mg, 60 mg and 180 mg Tablets, the generic versions of Aventis' Allegra Tablets. On Sept 6, 2005 BRL and TEVA announced that they had entered into an agreement and launched the Fexofenadine Hydrochloride Tablet products.
Allegra sales HAD to drop, and in today�s society where medicare is a huge burden, courts are to favor generics �who is honestly surprised??? The Hungarian endeavor is rather interesting, Comgenex seems to be a stable company. But European companies can be difficult to absorb, work hours, traditions, culture are quite different. AMRI is getting back into purchase mode, their previous attempts cost them quite a bit without success, I hope that they did their homework better this time, we shall see